Management
Dean J. Welsch, PhD
Chief Executive Officer (interim)/Chief Scientific Officer
Dr. Welsch received a BS in Chemistry from Hope College, a PhD in Biochemistry from the University of Minnesota in the lab of Dr. G. Nelsestuen, and completed his post-doctoral training with Dr. P. Friedman at Merck Research Labs. He has co-authored more than 35 peer-reviewed publications and is a co-inventor on 7 patents.
Edward Garmey, MD
Chief Medical Officer
A former academic hematologist-oncologist, Edward Garmey has served as Chief Medical Officer for leading private and public biopharmaceutical companies during his 17 years in industry. Prior to a transition into consulting in 2015, Dr. Garmey served as Chief Medical Officer and Senior Vice President at Cerulean Pharma where he oversaw the initiation of multi-national clinical trials for multiple drug programs and helped lead the company’s successful $67 MM IPO. Prior to industry, Dr. Garmey served as a pediatric hematologist-oncologist at Memorial Sloan-Kettering Cancer Center (MSKCC). He is an alumnus of Harvard and New York Universities and completed his medical training at New York’s Mount Sinai Medical Center, the Children’s Hospital of Los Angeles and MSKCC. Dr. Garmey completed additional research fellowships at the National Institutes of Health and the Botswana-Harvard Partnership for H.I.V. Research in Gaborone, Botswana and he is the recipient of the young investigators awards from the American Society of Hematology and the American Heart Association. Dr. Garmey resides in the Boston area where he serves as an adjunct instructor at Harvard Medical School’s Graduate Program in Therapeutic Science and as a member of the Board of Overseers at the Beth Israel Deaconess Medical Center.